News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Related Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News TX RX Systems Launches 700 MHz TX/RX Tower Top Amplifier (TTA) – Leading the Way in Public Safety Communication Technology News Click Armor and Carahsoft Partner to Bring Interactive Cyber Security Training Solutions to the Public Sector News YXT.com Group Holding Limited Expands Customer Base to Include Over 200 Fortune 500 Companies in China, Reinforcing Its Leadership in Digital Learning Solutions News New HackerRank Research Highlights How GenAI is Changing Software Development News Orezone Intersects 1.64 g/t Gold Over 46.00m Significantly Extending Mineralization 240m Below Life of Mine Reserve Pit News East Asia Super League Names Tradable Bits Official Fan Engagement Partner
